By: IPP Bureau
Last updated : November 05, 2026 11:06 am
Alembic Pharmaceuticals Limited reported a massive 81% year-on-year surge in consolidated profit after tax (PAT) to Rs. 335 crore for the second quarter of fiscal year 2027, driven by robust performance across its international and domestic segments.
The Vadodara-headquartered drugmaker registered a 36% jump in revenue from operations, touching Rs. 2,603 crore compared to Rs. 1,910 crore in the corresponding quarter of the previous fiscal year. Operational profitability also expanded significantly, with EBITDA surging 78% to Rs. 578 crore and margins stabilizing at 22%.
For the first half of FY27, Alembic’s cumulative consolidated revenue rose 31% to Rs. 4,753 crore, backed by a 64% expansion in US formulations (Rs. 1,781 crore) and a 10% rise in India branded sales (Rs. 1,367 crore).
Commenting on the results, Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum as Ex-US and API continued their growth trajectories. In India Branded, improving momentum in chronic therapies is strengthening the quality of growth, while in US Branded, we are encouraged by the traction building across our existing portfolio. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders”
The United States formulations business emerged as the primary growth engine, soaring 77% year-on-year to Rs. 1,003 crore. The company introduced three new products in the US market during the quarter and accumulated 245 cumulative Abbreviated New Drug Application (ANDA) approvals.
The domestic branded formulation portfolio grew 14% to Rs. 725 crore, outpacing broader industry trajectories. Key therapeutic areas such as gynecology, cardiology, gastroenterology, and ophthalmology recorded strong demand.
The Active Pharmaceutical Ingredient (API) business climbed 39% to Rs. 436 crore, while the ex-US international formulations business grew 12% to Rs. 440 crore.